Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

BACKGROUND: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. METHODS: Open-label, single-arm, 48-week pilot trial. HIV-1 infected...

Descripción completa

Detalles Bibliográficos
Autores principales: De Miguel, Rosa, Rial-Crestelo, David, Dominguez-Dominguez, Lourdes, Montejano, Rocío, Esteban-Cantos, Andrés, Aranguren-Rivas, Paula, Stella-Ascariz, Natalia, Bisbal, Otilia, Bermejo-Plaza, Laura, Garcia-Alvarez, Mónica, Alejos, Belén, Hernando, Asunción, Santacreu-Guerrero, Mireia, Cadiñanos, Julen, Mayoral, Mario, Castro, Juan Miguel, Moreno, Victoria, Martin-Carbonero, Luz, Delgado, Rafael, Rubio, Rafael, Pulido, Federico, Arribas, José Ramón
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225620/
https://www.ncbi.nlm.nih.gov/pubmed/32408111
http://dx.doi.org/10.1016/j.ebiom.2020.102779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225620/
https://www.ncbi.nlm.nih.gov/pubmed/32408111
http://dx.doi.org/10.1016/j.ebiom.2020.102779

Ejemplares similares